Kisho

Kezar Life Sciences, Inc. — Rare Disease Pipeline | Kisho

Kezar Life Sciences, Inc.

Other

Orphan Designations

0 approved, 2 designated

FDA Approvals

Active Trials

Rare Diseases

across 4 areas

News (30d)

Quiet

Kezar Life Sciences, Inc. is a company with 2 orphan drug designations across 2 rare diseases.

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 2

2 total diseases

Disease	Drug(s)	Stage
dermatomyositis	(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate	Des.TrialAppr.
polymyositis	(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate	Des.TrialAppr.